1. Home
  2. PDCO vs NTLA Comparison

PDCO vs NTLA Comparison

Compare PDCO & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PDCO
  • NTLA
  • Stock Information
  • Founded
  • PDCO 1877
  • NTLA 2014
  • Country
  • PDCO United States
  • NTLA United States
  • Employees
  • PDCO N/A
  • NTLA N/A
  • Industry
  • PDCO Medical Specialities
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • PDCO Health Care
  • NTLA Health Care
  • Exchange
  • PDCO Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • PDCO 1.9B
  • NTLA 1.4B
  • IPO Year
  • PDCO 1992
  • NTLA 2016
  • Fundamental
  • Price
  • PDCO $21.15
  • NTLA $16.04
  • Analyst Decision
  • PDCO Hold
  • NTLA Buy
  • Analyst Count
  • PDCO 8
  • NTLA 17
  • Target Price
  • PDCO $27.25
  • NTLA $58.63
  • AVG Volume (30 Days)
  • PDCO 709.9K
  • NTLA 2.8M
  • Earning Date
  • PDCO 11-27-2024
  • NTLA 11-07-2024
  • Dividend Yield
  • PDCO 4.74%
  • NTLA N/A
  • EPS Growth
  • PDCO N/A
  • NTLA N/A
  • EPS
  • PDCO 1.83
  • NTLA N/A
  • Revenue
  • PDCO $6,533,269,000.00
  • NTLA $45,967,000.00
  • Revenue This Year
  • PDCO $2.74
  • NTLA $49.33
  • Revenue Next Year
  • PDCO $3.25
  • NTLA $9.99
  • P/E Ratio
  • PDCO $11.59
  • NTLA N/A
  • Revenue Growth
  • PDCO 0.13
  • NTLA N/A
  • 52 Week Low
  • PDCO $19.89
  • NTLA $13.95
  • 52 Week High
  • PDCO $32.58
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • PDCO 54.57
  • NTLA 46.35
  • Support Level
  • PDCO $20.16
  • NTLA $14.55
  • Resistance Level
  • PDCO $22.37
  • NTLA $16.98
  • Average True Range (ATR)
  • PDCO 0.52
  • NTLA 1.04
  • MACD
  • PDCO 0.10
  • NTLA 0.01
  • Stochastic Oscillator
  • PDCO 66.97
  • NTLA 41.48

About PDCO Patterson Companies Inc.

Patterson Companies Inc is a dental distributor and wholesaler of consumable products and equipment operating through two business segments, Patterson Dental, and Patterson Animal Health. The company's segment includes Dental, Animal Health, and Corporate. It generates maximum revenue from the Animal Health segment. Geographically, it derives its revenue from the United States, the United Kingdom, and Canada. The firm derives almost all of its revenue from the United States.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: